In recent years, the pharmaceutical business has faced unprecedented challenges. The last three years have seen a 24% increase in the average cost of medications in the US due to safety concerns, issues with specific prescriptions, and competition from both non-generic and generic treatments. This resulted in a 4% drop in prescription expenses for those with private insurance between 2010 and 2013.Developing nations like China, India, and Brazil have comparable difficulties. Creating a line of vaccines with therapeutic qualities is one such intervention.In order to treat bacterial illnesses a